Video

Dr. Goy on Novel Therapies at the JTCC Conference

Dr. Andre Goy from John Theurer Cancer Center on Integrating Novel Therapies Into the JTCC Conference

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses how novel treatment options have revolutionized treatment for patients with non-small cell lung cancer, a disease that used to be considered “beyond surgery.”

Novel therapies, new characterizations of tumors, and a more personalized approach to treating these tumors will be discussed at the upcoming New Frontiers In The Management of Solid and Liquid Tumors conference at John Theurer Cancer Center at Hackensack University Medical Center, November 3-4, 2011.

Related Videos
Minoo Battiwalla, MD, MS
Cynthia X. Ma, MD, PhD
Jyoti Patel, MD
Leo I. Gordon, MD
Bertram Yuh, MD, MISM, MSHCPM
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.